患有BRAF V600E突变的转移性结直肠癌患者对第三线组合疗法的持久反应:一个病例报告
Qun Zhang1, Li Li1, Xiaoping Qian1
1Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China.
Human vaccines & immunotherapeutics
|February 25, 2025
概括
具有BRAFV600E突变的转移性结直肠癌 (mCRC) 具有挑战性治疗. 免疫疗法,放射疗法和向疗法的联合疗法在一个耐火性mCRC的患者中实现了持久的完整反应.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 癌症研究 癌症研究
背景情况:
- 患有BRAFV600E突变的转移性结直肠癌 (mCRC) 的预后不佳.
- BRAFV600E突变驱动异常信号,导致药物耐药性并影响患者的生存.
- 用BRAFV600E突变治疗晚期或耐火的mCRC仍然是一个重大的临床挑战.
研究的目的:
- 报告一个患有不耐火转移性结直肠癌 (mCRC) 的患者成功治疗的病例,该病例含有BRAFV600E突变.
- 在具有挑战性的mCRC亚型中评估组合治疗方案的疗效.
主要方法:
- 一名患有转移性结直肠癌 (mCRC) 和原发性和转移性部位的BRAFV600E突变的患者接受了治疗.
- 患者在二线治疗失败后接受了组合治疗,包括免疫治疗 (tislelizumab),放射治疗和向治疗 (fruquintinib).
- 综合成像和瘤标志物监测被用于评估.
主要成果:
- 患者在12个多月内实现并保持完整反应 (CR).
- 组合疗法在患有耐火性BRAFV600E突变mCRC的患者中显示出显著的疗效.
- 摘要中没有提到任何不良事件.
结论:
- 结合疗法包括免疫疗法,放射疗法和向疗法可以有效治疗BRAFV600E突变转移性结直肠癌.
- 这种方法为耐火性mCRC和预后不佳的患者提供了潜在的治疗策略.
- 需要进一步的研究,以在更大的队列中探索这种组合疗法.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463


